🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12173058

Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Mereo Biopharma 3 Limited · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173061

Compositions and methods for treatment of chronic lung diseases

The Board of Regents of the University of Texas System · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12161755

Sustained release device for treatment of Parkinson's disease and other disorders

Regents of the University of Minnesota · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12161607

Combination of cannabinoids in the treatment of leukemia

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12162821

Treatment of cataplexy

AXSOME MALTA LTD. · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12162855

Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers

THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12157891

Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12156862

Medicaments for the treatment of vasoconstriction related diseases or disorders

Sulfateq B.V. · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12150777

Treatment of depression

United States Government as represented by the Department of Veterans Affairs · Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12146139

Oligonucleotide interference treatments of prostate cancer

The Board of Regents of the University of Oklahoma · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144801

Methods and compositions for treatment of epileptic disorders

OVID THERAPEUTICS INC. · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144809

Treatment of prostate cancer

Takeda Pharmaceutical Company Limited · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12145925

Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treat

The Regents of the University of California · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12138247

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12138274

Compositions and methods for the treatment of peripheral artery disease and cardiopulmonar

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12139711

Antisense oligonucleotides for the treatment of Leber congenital amaurosis

Stichting Radboud universitair medisch centrum · Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12134767

Materials and methods for treatment of hemoglobinopathies

Vertex Pharmaceuticals Incorporated · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12134650

Compositions targeting GABRA2 and methods for diagnosis and treatment of cancer

TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12128015

APE/REF1 inhibitors for the treatment of cancer

The Regents of the University of California · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12128013

Toxic aldehyde related diseases and treatment

Aldeyra Therapeutics, Inc. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12128048

Combination therapies using PRMT5 inhibitors for the treatment of cancer

Mirati Therapeutics, Inc. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12128090

Methods of prophylactic treatment using recombinant VWF (rVWF)

Takeda Pharmaceutical Company Limited · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12129471

Materials and methods for treatment of human genetic diseases including hemoglobinopathies

Vertex Pharmaceuticals Incorporated · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12122998

Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosom

CRISPR THERAPEUTICS AG · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted